Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Sangamo Therapeutics (SGMO) Non-Current Receivables (2023 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Non-Current Receivables for 3 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • For Q4 2025, Non-Current Receivables fell 30.22% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $8.9 million, down 30.22%, while the annual FY2025 figure was $8.9 million, 30.22% down from the prior year.
  • Non-Current Receivables hit $8.9 million in Q4 2025 for Sangamo Therapeutics, down from $14.5 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $15.4 million in Q4 2023 and bottomed at $8.9 million in Q4 2025.
  • Average Non-Current Receivables over 3 years is $13.2 million, with a median of $13.9 million recorded in 2025.
  • Year-over-year, Non-Current Receivables fell 16.62% in 2024 and then crashed 30.22% in 2025.
  • Sangamo Therapeutics' Non-Current Receivables stood at $15.4 million in 2023, then dropped by 16.62% to $12.8 million in 2024, then tumbled by 30.22% to $8.9 million in 2025.
  • According to Business Quant data, Non-Current Receivables over the past three periods came in at $8.9 million, $14.5 million, and $14.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.